ONCAlert | Upfront Therapy for mRCC
Videos  >  

Navigating Treatment Options for Patients With Relapsed/Refractory CLL

Danielle M. Brander, MD
Published Online:2:44 PM, Tue July 17, 2018


Danielle M. Brander, MD, assistant professor of medicine at Duke University School of Medicine and member of the Duke Cancer Institute, discusses a major challenge in the field of chronic lymphocytic leukemia (CLL). She says the biggest challenge to overcome in the treatment of patients with CLL is navigating areas where research is not yet mature. 

For example, it is still unclear how some novel agents in the frontline setting do long-term for favorable-risk patients. Additionally, agents for the relapsed/refractory setting have been randomized to chemotherapy in phase II trials, but how can these agents be compared to decide the best treatment? 

Brander says that many patients ask about venetoclax/rituximab (Venclexta/Rituxan), as the combination has been approved for all relapsed/refractory patients. However, if patients have had prior chemotherapy, experts do not know if they should use the combination or ibrutinib (Imbruvica) next. There are currently more long-term data on sequencing from ibrutinib to venetoclax, but not venetoclax to ibrutinib. Brander expects that we will learn more on this soon.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.